



## Press Release

# Active Biomarkers and Cynbiose sign a comarketing agreement

Lyon, France – December 06, 2021 – Active Biomarkers and Cynbiose are pleased to announce that they have entered into a comarketing and business agreement to strengthen their more than 10-year collaboration.

Active Biomarkers is a leading **assay development and specialty bioanalytical laboratory** whose expert team of scientists and large technology panels are instrumental in the development, qualification, validation, and small to large scale sample testing of hundreds of assays, supporting regulatory filings of tens of innovative therapies. Active Biomarkers is renowned for its expertise in oncology, infectious diseases, inflammation and neurodegenerative disorders.

Cynbiose is a specialty **Contract Research Organization (CRO)** unique in Europe. The company is specialized in **preclinical research services** with a core expertise and focus on the non-human primate (NHP) model. The company also develops innovative **clinically relevant models** across multiple therapeutic areas to accelerate the discovery of drug candidates.

“Leveraging the technical complementarity, the geographic proximity and our longstanding and successful collaboration with Cynbiose will help us continue to provide superior services and unrivaled expertise in assay development based on a client-centric team approach and short development time” said Dr Marc Essodaigui, President and CEO of Active Biomarkers.

“Offering our clients, a fully integrated suite of services, including **exploratory pharmacokinetics and pharmacodynamics studies, early safety studies, hybrid exploratory designs, biomarkers and efficacy studies** using original NHP models to bridge the gap between preclinical and clinical development is quite unique in Europe” added Dr Hugues Contamin, Founder and CEO of Cynbiose. “We are delighted to reinforce our collaboration with Active Biomarkers with whom we share human and entrepreneurial values as well as complementary scientific and technical expertise.”

Through this agreement, the two companies copromote their respective services and offer their clients a fully integrated scientific and technical solution to advance innovative therapies in multiple therapeutic areas.

## **About Active Biomarkers**

Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in more than 1000 m<sup>2</sup> BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of-the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms.

[www.activebiomarkers.com](http://www.activebiomarkers.com)

## **About Cynbiose**

Founded in 2008, Cynbiose is the only preclinical Contract Research Organization (CRO) of its kind in Europe and is AAALAC accredited. The company specializes in the development and commercialization of innovative non-human primate models to accelerate the preclinical development phases of drug candidates. It works on exploratory DMPK and toxicology studies, as well as proof of concept studies in different human pathologies, such as infectious diseases and respiratory conditions, the central nervous system and inflammatory, musculoskeletal disorders and cardiovascular/neurovascular diseases. The company provides its services in line with quality guidelines that meet industry requirements. It boasts an extensive network of experts and partners in the academic and private domains, allowing complex studies to be conducted with dedicated project teams. Cynbiose is committed, responsible and proud to contribute to advancing healthcare research by participating in numerous preclinical development programs for new therapies. The SME Cynbiose is headed by CEO Dr Hugues Contamin (DVM, PhD) and is based in Marcy l'Etoile near Lyon, France. Cynbiose is a founding member of the French Association of Service and Innovation Companies for the Life Sciences (AFSSI).

[www.cynbiose.com](http://www.cynbiose.com)

## **Media contacts**

### **Active Biomarkers**

Magali ROCHE  
*Business Development Director*

[info@active-biomarkers.com](mailto:info@active-biomarkers.com)

### **Cynbiose**

Cécile Durand  
*Business development & marketing manager*

[contact@cynbiose.com](mailto:contact@cynbiose.com)